Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine

Inclusion Criteria: * Adults aged 40-65 years in stable health; * The subjects can understand and voluntarily sign the informed consent form; * Proven legal identity. Exclusion Criteria: * Have received any pneumococcal vaccine; * History bacterial pneumonia or invasive pneumococcal infectious diseases caused by pneumococci and confirmed by culture; * Women of childbearing age (menarche to premenopause) are pregnant (including positive urine pregnancy test), breastfeeding or planning pregnancy within 1 month; * History of asthma, allergy to vaccines or vaccine components, and serious adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema; * Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.; * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * Autoimmune disease or immune deficiency/immunosuppression; * Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; * Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; * A long history of alcohol or drug abuse; * Receipt of blood products within in the past 3 months; * Receipt of other investigational drugs within 30 days prior to receiving the investigational vaccine; * Receipt of attenuated live vaccines or COVID-19 vaccines in the past 14 days; * Receipt of inactivated or subunit vaccines in the past 7 days; * Onset of various acute or chronic diseases within 7 days prior to the study; * Underarm body temperature before vaccination\>37.0°C; * The subjects participated in other clinical trials during the follow-up period or will be planned to participate other clinical trials within 1 months; * According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.